PARTICIPATION IN CANCER AND LEUKEMIA GROUP B

参与癌症和白血病 B 组

• 批准号: 3556558
• 负责人: DAVID B DUGGAN
• 金额: $ 21.31万
• 依托单位: UPSTATE MEDICAL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1993-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556558
• 关键词: Retroviridae; acute leukemia; anthracyclines; biological response modifiers; biopsy; bone marrow transplantation; breast neoplasms; cancer information system; cancer rehabilitation mental health service; clinical trials; clone cells; combination cancer therapy; cooperative study; cytogenetics; cytosine arabinoside; diagnosis design /evaluation; drug adverse effect; drug design /synthesis /production; drug metabolism; human subject; human therapy evaluation; interferons; lymphoma; medical education; medical outreach /case finding; monoclonal antibody; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; pediatric neoplasm /cancer; radioimmunoassay; tumor necrosis factor alpha

This proposal requests continuation funding for institutional participation of the SUNY Health Science Center (Upstate Medical Center) Syracuse, New York, in the clinical research activities of Cancer and Leukemia Group B (CALGB). CALGB is a multi-institutional cooperative reserach group dedicated to the systematic planning, initiation, conduct analysis, and reporting of research as applied to therapy of patients with malignant disease. The scope of interest of CALGB and our institutional participation includes a wide variety of malignant disorders. The current CALGB proposal involves an increase in laboratory-based evaluations as well. The program in oncology at our institution in conjunction with CALGB is truly interdisciplinary, involving the active participation of Surgery, Radiotherapy, Clinical Pathology, Psychiatry, Pathology, Cytogenetics and Internal Medicine (Hematology and Medical Oncology). The Upstate Medical Center actively participates in all phases of the CALGB program. Our personnel contribute heavily to, and are prominent in, group scientific and administrative leadership, new study design and chairmanship, development and execution of pilot studies, the testing of new chemotherapeutic agents in phase I and phase II trials in addition to the accrual of greater than 150 patient entries/year to group protocols. The Leukemia Reference Laboratory for the entire group and the Committee Chairmanship in Lymphoma are located at our institution. As a result of the funding provided by this proposal and our institutional commitment, the accrual rate for patients entered into controlled, evaluable, experimental cancer therapy will be maintained at the current high level. The broadening and deepening of the clinical research program at our institution will similarly be reflected in the depth and breadth of our scientific and administrative involvement in CALGB activities. Since our institutional participation with CALGB is the core of the interdisciplinary cancer program at our institution, additional salutary effects will continue to be evident in the education of medical students, house officers, nursing staff as well as in the continuing education of physicians in mid-New York State. In addition, the collaboration with CALGB will help translate the most recent advances in medical care and expertise to a large and diversified patient population.

该提案要求继续为机构提供资金 纽约州立大学健康科学中心（上州）的参与 医学中心）纽约州锡拉丘兹，从事临床研究 癌症和白血病 B 组 (CALGB) 的活动。 CALGB 是 一个多机构合作研究小组，致力于 系统规划、启动、进行分析和报告 研究应用于恶性疾病患者的治疗。 CALGB 和我们机构的利益范围 参与包括多种恶性疾病。 这 当前的 CALGB 提案涉及增加基于实验室的 评价也是如此。 我们机构的肿瘤学项目 与 CALGB 的结合是真正的跨学科，涉及 外科、放射治疗、临床病理学的积极参与， 精神病学、病理学、细胞遗传学和内科 （血液学和肿瘤内科）。 北部医疗中心 积极参与 CALGB 计划的所有阶段。 我们的 人员对团体作出重大贡献并在团体中表现突出 科学和行政领导、新的研究设计和 主持、开发和执行试点研究， 新化疗药物的I期和II期测试 除了超过 150 名患者的累积试验之外 条目/年分组协议。 白血病参考资料 整个集团的实验室和委员会主席 淋巴瘤位于我们的机构。 由于 该提案和我们的机构提供的资金 承诺，患者的应计率 受控的、可评估的、实验性的癌症治疗将是 维持在目前的较高水平。 拓宽和 我们机构临床研究计划的深化将 同样也反映在我们科学的深度和广度上 CALGB 活动的行政参与。 自从我们的 CALGB 的机构参与是该计划的核心 我们机构的跨学科癌症计划，额外 教育方面的有益效果将继续显现 医学生、住院医师、护理人员以及 纽约州中部的医生继续教育。 在 此外，与 CALGB 的合作将有助于转化 医疗保健和专业知识的最新进展 患者群体多样化。